menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Bayer files for approval of finerenone in heart failure in Japan

    INDPHARMAPOST

    Bayer’s pharma growth strategy progressing well as pipeline

    INDPHARMAPOST

    Bayer`s Kerendia Reduces Cardio Death Risk By 16% In Heart Failure Patients

    FIERCE PHARMA

    ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data

    BUSINESSWIRE

    Bayer`s KERENDIA® Achieves Primary Endpoint In FINEARTS-HF Study

    BUSINESSWIRE

    Bayer to present real-world study data of Kerendia for the progression of CKD

    PHARMABIZ

    Bayer reports drop in Q1 sales amidst patent litigation challenges

    PHARMACEUTICAL TECHNOLOGY

    Finerenone CKD/T2D/Heart Failure Pooled Analysis Design At Heart Failure 2024

    BUSINESSWIRE

    Bayer KERENDIA Data At Heart Failure Congress 2024

    BUSINESSWIRE

    Data Provides Additional Insights on Hyperkalemia and Safety of Kerendia

    BUSINESSWIRE

    New Kerendia™ (finerenone) data show impact of early albuminuria reduction

    PRESS RELEASE

    New Human Biomarker Findings Support Mechanism of Action of Kerendia

    BUSINESSWIRE

    USDMF for Finerenone API has been submitted to the USFDA

    PRESS RELEASE

    Bayer Expands Clinical Devp Program Investigating Finerenone for Heart Failure

    BUSINESSWIRE

    Bayer’s Kerendia Included in Latest Focused Clinical Updates from EU Cardiology

    BUSINESSWIRE

    CPC Announces Initiation of MOONRAKER Program - 3 Trials Evaluating Finerenone

    ACCESSWIRE

    Bayer to Investigate Finerenone in Ph III Study in Adults Withckd With Ty1 D

    BUSINESSWIRE

    Bayer to present data on Kerendia from comprehensive clinical trial program

    PRESS RELEASE

    China NMPA grants expanded indication of Bayer’s Kerendia

    PHARMABIZ

    Kerendia™ (finerenone) granted expanded indication in China

    PRESS RELEASE

    Bayer`s potential blockbusters Nubeqa, Kerendia thrive in Q1

    FIERCE PHARMA

    Bayer`s Kerendia (Finerenone) Approved In Europe

    EMA

    Kerendia granted expanded indication in EU for patients with CKD

    PHARMABIZ

    New therapy option Kerendia reduces cardio-renal risk in chronic kidney disease

    PRESS RELEASE

    Bayer starts work on $43M+ expansion of OTC manufacturing site in Pennsylvania

    ENDPTS

    Scottish Medicines Consortium approves Bayer’s Kerendia for NHS Scotland

    PHARMAFILE

    Bayer to Highlight Additional Analyses From Comprehensive KERENDIA (finerenone)

    BUSINESSWIRE

    Bayer’s KERENDIA Recommended as Part of Comprehensive Treatment Strategy

    BUSINESSWIRE

    Bayer KERENDIA Receives Updated Label to Include Findings From PIII FIGARO-DKD

    BUSINESSWIRE

    Bayer’s Kerendia Cuts Death in Diabetes, Chronic Kidney Disease

    FIERCEPHARMA

    New data indicate positive effects of Kerendia™ (finerenone) on mortality in patients with chronic kidney disease and type 2 diabetes

    PRESS RELEASE

    Bayer launches Kerendia to slow down progression of CKD

    PHARMABIZ

    Bayer to Present Data From CVS Portfolio, Presentation for KERENDIA

    BUSINESSWIRE

    Bayer’s KERENDIA Receives Recommendations From ADA With CKD Associated With T2D

    BUSINESSWIRE

    Bayer’s Kerendia to compete against SGLT-2 inhibitors

    KOREABIOMED

    Bayer Presents New Subgroup Analyses for KERENDIA for CKD Associated With T2D

    BUSINESSWIRE

    Bayer gets Japanese MHLW marketing approval for Kerendia in CKD and T2D

    PHARMABIZ

    Bayer`s Biologic Kerendia (Finerenone) Receives Approval in Europe

    EMA

    MHRA authorisation of new treatment for CKD associated with diabetes

    PHARMAFILE

    EC grants MAA to Bayer’s Kerendia for CKD associated with type 2 diabetes

    PHARMABIZ

    Evofem Biosciences, Orion Biotechnology Enter OB-002 Alliance

    CONTRACTPHARMA

    Bayer Presented New Analyses Investigating KERENDIA on Cardiovascular Outcomes

    BUSINESSWIRE

    Bayer bullish on Kerendia after SGLT2 combo showing

    FIERCEPHARMA

    Bayer to present new analyses adding to the depth of knowledge on KERENDIA®

    BUSINESSWIRE

    Bayer Phase III trial results prove positive for diabetes patients

    PHARMAFILE

    Bayer initiates phase III FIND-CKD study of Kerendia in nondiabetic CKD

    PHARMABIZ

    Bayer Extends Clinical Development Program for KERENDIA With PIII Study in CKD

    BUSINESSWIRE

    Bayer`s Kerendia racks up cardio benefits in outcomes trials

    FIERCEPHARMA

    Finerenone Improves Cardiovascular, Renal Outcomes in Patients With CKD & T2DM

    ESCARDIO

    Bayer Announces KERENDIA® Reduces the Risk of Cardiovascular Outcomes

    BUSINESSWIRE

    Bayer touts Kerendia`s blockbuster potential

    FIERCEPHARMA

    FDA Approval of Kerendia to Help Slow Kidney Disease and Failure linked with T2D

    PR NEWSWIRE

    Bayer’s Kerendia approved in the US to slow CKD in type 2 diabetes patients

    PHARMATIMES

    FDA Approves Drug to Reduce Risk of Serious Kidney and Heart Complication

    FDA

    Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval

    BUSINESSWIRE

    Bayer gets USFDA nod for KERENDIA (finerenone) to treat CKD associated with T2DM

    EXPRESS PHARMA

    Bayer wins priority review for CKD program finerenone after PhIII data

    ENDPTS

    Bayer`s heart drug helps patients regardless of medical history

    FIERCE BIOTECH

    Bayer submits marketing authorization applications for finerenone in the U.S.

    PRESS RELEASE

    Bayer`s heart failure pill hinders kidney, heart diseases

    FIERCE BIOTECH

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.